Parikh Jash S, Randhawa Arshdeep K, Wharton Sean, Edgell Heather, Kuk Jennifer L
York University, School of Kinesiology and Health Science, Toronto, ON, Canada M3J 1P3.
The Wharton Medical Clinic, Toronto, ON, Canada M4J 5B9.
J Obes. 2018 Oct 1;2018:4573258. doi: 10.1155/2018/4573258. eCollection 2018.
One in three US adults is living with obesity or hypertension, and more than 75% of hypertensive individuals are using antihypertensive medications. Therefore, it is important to examine blood pressure (BP) differences in populations that are using these medications with differing obesity status.
We examined whether BP attained when using various antihypertensive medications varies amongst different body mass index (BMI) categories and whether antihypertensive medication use is associated with differences in other metabolic risk factors, independent of BMI.
Adults with hypertension from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2014 were used (=15,285). Linear regression analyses were used to examine the main effects and interaction between antihypertensive use and BMI.
In general, users of antihypertensive medications had lower BP than those not taking BP medications (NoBPMed) ( < 0.05), whereby in women, the differences in systolic BP between angiotensin-converting-enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) users and NoBPMed were greater in those with obesity (ACE inhibitors: -14 ± 1 mmHg; ARB: -16 ± 1 mmHg) compared to normal weight individuals (ACE inhibitors: -9 ± 1 mmHg; ARB: -11 ± 1 mmHg) ( < 0.05). Diastolic BP differences between women ARB users and NoBPMed were also greatest in obesity (-5 ± 1 mmHg) ( < 0.05) whilst there were no differences in normal weight individuals (-1 ± 1 mmHg) (>0.05). Furthermore, glucose levels and waist circumference in women were higher in those using ACE inhibitors compared to diuretics ( < 0.05).
ACE inhibitors and ARBs may be associated with more beneficial BP profiles in women with obesity, with no obesity-related BP differences for antihypertensive medication in men. However, there could be potential cardiometabolic effects for some antihypertensive medications that should be explored further.
三分之一的美国成年人患有肥胖症或高血压,超过75%的高血压患者正在使用抗高血压药物。因此,研究使用这些药物的不同肥胖状况人群的血压(BP)差异很重要。
我们研究了使用各种抗高血压药物时达到的血压在不同体重指数(BMI)类别之间是否存在差异,以及抗高血压药物的使用是否与其他代谢风险因素的差异相关,且独立于BMI。
使用1999年至2014年美国国家健康和营养检查调查(NHANES)中的高血压成年人(=15285)。线性回归分析用于检验抗高血压药物使用与BMI之间的主要效应和相互作用。
总体而言,抗高血压药物使用者的血压低于未服用血压药物者(NoBPMed)(<0.05),其中在女性中,肥胖者使用血管紧张素转换酶(ACE)抑制剂或血管紧张素受体阻滞剂(ARB)者与NoBPMed者之间的收缩压差异大于正常体重者(ACE抑制剂:-14±1mmHg;ARB:-16±1mmHg)(<0.05)。女性ARB使用者与NoBPMed者之间的舒张压差异在肥胖者中也最大(-5±1mmHg)(<0.05),而在正常体重者中无差异(-1±1mmHg)(>0.05)。此外,与利尿剂使用者相比,使用ACE抑制剂的女性的血糖水平和腰围更高(<0.